Cargando…
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV
BACKGROUND: Anti vascular endothelial growth factor (VEGF) therapy is an established treatment for various retinal diseases. Long-term data on injection frequencies and visual acuity (VA), however, are still rare. METHODS: Five-year analysis of real-life VA developments and injection patterns from 2...
Autores principales: | Wecker, Thomas, Ehlken, Christoph, Bühler, Anima, Lange, Clemens, Agostini, Hansjürgen, Böhringer, Daniel, Stahl, Andreas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339568/ https://www.ncbi.nlm.nih.gov/pubmed/27215744 http://dx.doi.org/10.1136/bjophthalmol-2016-308668 |
Ejemplares similares
-
Anti-VEGF injection frequency correlates with visual acuity outcomes in pro re nata neovascular AMD treatment
por: Wecker, Thomas, et al.
Publicado: (2019) -
Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients
por: Ehlken, Christoph, et al.
Publicado: (2017) -
OCT Angiography of the Choriocapillaris in Central Serous Chorioretinopathy: A Quantitative Subgroup Analysis
por: Cakir, Bertan, et al.
Publicado: (2019) -
Initial Pro Re Nata Brolucizumab for Exudative AMD: The PROBE Study
por: Bilgic, Alper, et al.
Publicado: (2021) -
Immunosenescence in Choroidal Neovascularization (CNV)—Transcriptional Profiling of Naïve and CNV-Associated Retinal Myeloid Cells during Aging
por: Schlecht, Anja, et al.
Publicado: (2021)